Form 4: Harvard Bioscience Director Receives Stock Award

Robert E. Gagnon, a Director at Harvard Bioscience Inc., was granted 16,556 restricted stock units, vesting prior to the next annual meeting or one year from grant.

Summary

• Robert E. Gagnon, a Director of Harvard Bioscience Inc., received an award of 16,556 restricted stock units (RSUs) on June 9, 2026.
• These RSUs will vest in full either immediately before the company's next annual meeting or one year from the grant date, whichever comes first.
• Following this award, Gagnon beneficially owns a total of 27,556 shares of common stock.
• This total includes the newly awarded RSUs and 11,000 shares of common stock.
• The reported share numbers have been adjusted to reflect a 10-for-1 reverse stock split that occurred on March 13, 2026. Previously, the 11,000 shares represented 110,000 vested RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine stock award to a director and does not contain significant financial performance data or strategic shifts.

Positives

• Director Robert E. Gagnon received a stock award, indicating continued alignment with company performance.
• The award of 16,556 restricted stock units suggests management confidence and a focus on long-term incentives.
• The total beneficial ownership of 27,556 shares by a director demonstrates a significant personal stake in the company's success.

Future Outlook

The restricted stock units awarded to Director Gagnon are set to vest either prior to the company's next annual meeting or one year from the grant date, whichever occurs first, indicating a near-term vesting schedule.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, including stock awards. This type of award is common in the biotechnology sector to incentivize and retain key personnel, aligning their interests with shareholders.

Stakeholder Impact

• Shareholders: The award of stock units to a director can be seen as a positive alignment of interests, but the direct financial impact is minimal without further context on company performance.
• Employees: This filing does not directly impact employees, but it reflects standard compensation practices for senior leadership.
• Management: The award reinforces the compensation structure for key executives and directors.

Next Steps

• Vesting of 16,556 restricted stock units prior to the company's next annual meeting or one year from the grant date.

Key Dates

Keywords

Form 4, SEC Filing, Stock Award, Restricted Stock Units, Director Compensation, Harvard Bioscience, HBIO, Beneficial Ownership, Insider Trading